Electrophysiological changes, plasma vascular endothelial growth factor, fatty acid synthase, and adhesion molecules in diabetic neuropathy

Neurosciences

Volumn 13, Issue 4, 2008, Pages 374-379

  Zakareia, Faten Abdulhady ^a,b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; VASCULOTROPIN;

ADULT; ANKLE BRACHIAL INDEX; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DIABETIC NEUROPATHY; ELECTROPHYSIOLOGY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOTOR NERVE CONDUCTION; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PERONEUS NERVE; SURAL NERVE; ULNAR NERVE;

EID: 55549127926     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Antoniades C, Tousoulis D, Tountas C, Tentolouris C, Toutouza M, Vasiliadou C, et al. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C. Diabet Med 2004; 21: 552-558.
2. Smith DG, Assal M, Reiber GE, Vath C, LeMaster J, Wallace C. Minor environmental trauma and lower extremity amputation in high-risk patients with diabetes: incidence, pivotal events, etiology, and amputation level in a prospectively followed cohort. Foot Ankle Int 2003; 24: 690-695.
3. Masuzawa K, Goto K, Jesmin S, Maeda S, Miyauchi T, Kaji Y, et al. An endothelin type A receptor antagonist reverses upregulated VEGF and ICAM-1 levels in streptozotocin-induced diabetic rat retina. Curr Eye Res 2006; 31: 79-89.
4. Stevens MJ, Feldman EL, Greene DA. Diabetic peripheral neuropathy. In: Current therapy of diabetes mellitus. St. Louis (USA); Mosby-Year Book Inc.; 1997. p.160-165.
5. Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst 2004; 9: 26-53.
6. Samii A, Unger J, Lange W. Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats. Neurosci Lett 1999; 262: 159-162.
7. Weisbrod CJ, Eastwood PR, O'Driscoll G, Walsh JH, Best M, Halliwill JR, et al. Vasomotor responses to hypoxia in type 2 diabetes. Diabetes 2004; 53: 2073-2078.
8. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hypermeability and angiogenesis. Am J Path 1995; 146: 1029-1039.
9. Isner JM, Ropper A, Hirst K. VEGF gene transfer for diabetic neuropathy. Hum Gene Ther 2001; 12: 1593-1594.
10. Seckin D, Ilhan N, Ilhan N, Ertugrul S. Glycaemic control, markers of endothelial cell activation and oxidative stress in children with type 1 diabetes mellitus. Diabetes Res Clin Pract 2006; 73: 191-197.
11. Toyozaki T, Hiroe M, Saito T. Levels of soluble Fas in patients with myocarditis, heart failure of unknown origin, and in healthy volunteers. Am J Cardiol 1998; 81: 798-800.
12. Pearl-Yafe M, Yolcu ES, Yaniv I, Stein J, Shirwan H, Askenasy N. The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation. Bioessays 2006; 28: 211-222.
13. Moriwaki M, Itoh N, Miyagawa J. Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset type I diabetes mellitus. Diabetologia 1999; 42: 1332-1340.
14. Srinivasan S, Stevens M, Wiley JW. Diabetic polyneuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes 2000; 49: 1932-1938.
15. Sokup A. Adhesion molecules in type 2 diabetes. Przegl Lek 2005; 62: 234-237.
16. Meleth AD, Agron E, Chan CC, Reed GF, Arora K, Byrnes G, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46: 4295-4301.
17. Varley H. Practical clinical biochemistry. 6th ed. London (UK): Heinemann Medical Books; 1988. p. 123-155.
18. Burtis CA, Ashwood ER. Teitz Textbook of Clinical Chemistry. 2nd ed. Philadelphia (PA): WB Saunders Co; 1994. p. 1715.
19. Veves A, King GL. Can VEGF reverse diabetic neuropathy in human subjects? J Clin Invest 2001; 107: 1215-1218.
20. Guillot R, Bringuier AF, Porokhov B, Guillausseau PJ, Feldmann G. Increased levels of soluble Fas in serum from diabetic patients with neuropathy. Diabetes Metab 2001; 27: 315-321 .
21. Kimura J. Principles and pitfalls of nerve conduction studies. Ann Neurol 1984; 16: 415-429.
22. Bril V, Buchanan RA. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2004; 27: 2369-2375.
23. Richards-George P. Vasculopathy in the diabetic foot. West Indian Med J 2001; 50 (Suppl 1): S18-S20.
24. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
25. Bausero P, Ben-Mahdi M, Mazucatelli J, Bloy C, Perrot-Applanat M. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen and hypoxia. Am J Physiol Heart Circ Physiol 2000; 279: H2033-H2042.
26. Wernig F, Xu Q. Mechanical stress-induced apoptosis in the cardiovascular system. Prog Biophys Mol Biol 2002; 78: 105-137.